Cosmos Health Target of Unusually High Options Trading (NASDAQ:COSM)

Cosmos Health Inc. (NASDAQ:COSM) was the recipient of some unusual options trading on Thursday. Stock investors purchased 2,716 call options on the company. This is an increase of 654% compared to the typical volume of 360 call options.

Insiders Place Their Bets

In other Cosmos Health news, CFO Georgios Terzis bought 168,135 shares of Cosmos Health stock in a transaction that occurred on Tuesday, June 16th. The stock was purchased at an average cost of $0.25 per share, for a total transaction of $42,033.75. Following the completion of the acquisition, the chief financial officer owned 2,235,398 shares of the company’s stock, valued at approximately $558,849.50. This represents a 8.13% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Grigorios Siokas acquired 349,825 shares of the business’s stock in a transaction dated Thursday, July 30th. The shares were bought at an average price of $0.20 per share, with a total value of $69,965.00. Following the transaction, the chief executive officer directly owned 14,597,917 shares in the company, valued at approximately $2,919,583.40. The trade was a 2.46% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 2,204,138 shares of company stock worth $457,137 in the last three months. Company insiders own 26.15% of the company’s stock.

Institutional Trading of Cosmos Health

A number of institutional investors have recently added to or reduced their stakes in COSM. Citadel Advisors LLC raised its holdings in shares of Cosmos Health by 133.1% during the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares in the last quarter. Renaissance Technologies LLC increased its position in Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock worth $167,000 after buying an additional 241,775 shares during the last quarter. XTX Topco Ltd raised its holdings in Cosmos Health by 52.1% during the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after buying an additional 34,117 shares in the last quarter. Finally, BlackRock Inc. acquired a new stake in shares of Cosmos Health in the second quarter worth about $49,000. 12.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Cosmos Health Stock Up 8.3%

Shares of COSM traded up $0.02 during trading hours on Thursday, reaching $0.21. The company’s stock had a trading volume of 1,740,404 shares, compared to its average volume of 4,458,653. The company has a 50 day moving average of $0.22 and a two-hundred day moving average of $0.30. The company has a quick ratio of 0.92, a current ratio of 1.08 and a debt-to-equity ratio of 0.31. The firm has a market cap of $12.55 million, a price-to-earnings ratio of -0.33 and a beta of 4.80. Cosmos Health has a 1-year low of $0.16 and a 1-year high of $1.32.

Cosmos Health (NASDAQ:COSM) last issued its earnings results on Wednesday, August 19th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.04). The company had revenue of $18.99 million for the quarter, compared to analyst estimates of $19.42 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. As a group, research analysts predict that Cosmos Health will post 0.01 EPS for the current fiscal year.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.